← Autolus Therapeutics plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $75k |
$84k
+12.00%
|
$1.4m
+1575.00%
|
$2.9m
+106.68%
|
$536k
-81.57%
|
$262k
-51.12%
|
$1.7m
+551.91%
|
$0
-100.00%
|
$10.1m |
$75.4m
+644.94%
|
$92.6m
+22.86%
|
|
| Total License revenue | $75k | $84k | $1.4m | $2.9m | $1.7m | $2.3m | $6.4m | $0 | $10.1m | $75.4m | — | |
| Cost of Revenue | $56k |
$63k
+12.00%
|
$1.1m
+1575.00%
|
$2.2m
+106.68%
|
$402k
-81.57%
|
$196k
-51.12%
|
$1.3m
+551.91%
|
$0
-100.00%
|
$7.6m |
$56.5m
+644.94%
|
$103.0m
+82.14%
|
|
| Reconciled Cost Of Revenue | — | — | — | — | — | — | — | $0 | $11.4m |
$96.4m
+746.31%
|
$103.0m
+6.87%
|
|
| Gross Profit | $19k |
$21k
+12.00%
|
$352k
+1575.00%
|
$727k
+106.68%
|
$134k
-81.57%
|
$66k
-51.12%
|
$427k
+551.91%
|
$1.7m
+297.66%
|
($1.3m)
-174.62%
|
($21.0m)
-1555.96%
|
($10.4m)
+50.61%
|
|
| Net Interest Income | — | — | — | — | — | — | ($7.2m) |
($31.6m)
-338.54%
|
$23.1m
+173.07%
|
($17.7m)
-176.71%
|
($22.3m)
-26.28%
|
|
| Research and development | ($10.4m) | ($16.0m) | ($36.1m) | ($105.4m) | ($134.9m) | ($134.8m) | ($142.0m) | $130.5m | $138.4m | $117.7m | $112.2m | |
| Selling, General and Administrative Expense | — | — | — | — | — | — | — | — | $101.1m | $131.9m | $142.3m | |
| Amortization of Intangible Assets | — | — | — | $47k | $91k | $90k | $65k | $0 | $162k | $1.5m | — | |
| Other Operating Expenses | — | — | — | — | — | ($823k) | ($166k) | — | — | — | — | |
| Operating Expenses | $14.4m | $23.4m | $57.5m | $146.1m | $168.1m | $165.0m | $168.0m | $179.7m | $241.4m | $270.5m | $254.5m | |
| Operating Income (Loss) | ($14.4m) |
($23.4m)
-62.90%
|
($57.5m)
-145.68%
|
($146.1m)
-153.88%
|
($168.1m)
-15.12%
|
($165.0m)
+1.87%
|
($168.0m)
-1.85%
|
($179.7m)
-6.94%
|
($241.4m)
-34.35%
|
($270.5m)
-12.06%
|
($264.8m)
+2.12%
|
|
| Interest income | $75k | $84k | $1.5m | $2.5m | $536k | $262k | $1.7m | $13.5m | $32.4m | $19.0m | $15.3m | |
| Net Non Operating Interest Income Expense | — | — | — | — | — | — | ($7.2m) | ($31.6m) | $23.1m | ($17.7m) | ($22.3m) | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | $4.0m | $4.6m | $200k | $2.3m | $1.8m | $2.6m | ($989k) | $2.2m | — | |
| Gain On Sale Of PPE | — | — | — | $0 | $0 | ($676k) | ($515k) | ($3.8m) | ($223k) | — | ($3k) | |
| Gain On Sale Of Security | — | — | — | — | — | — | — | $2.6m | ($989k) | $2.2m | ($1.7m) | |
| Other Nonoperating Income (Expense) | ($26k) | ($46k) | $4.0m | $4.5m | $1.4m | ($145k) | $2.0m | $2.9m | $220k | $515k | — | |
| Other income (expense) | ($26k) | ($46k) | $4.0m | $4.5m | $1.4m | ($145k) | $2.0m | ($1.3m) | ($769k) | $2.7m | ($1.2m) | |
| Interest Expense (non-operating) | — | — | — | $0 | $0 | $1.1m | $8.9m | $45.1m | $9.3m | $36.7m | $37.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | ($209.8m) | ($221.7m) | ($290.1m) | ($288.4m) | |
| Pre-Tax Income | — | — | — | — | — | — | ($148.6m) | ($208.4m) | ($219.1m) | ($285.6m) | ($288.4m) | |
| Net loss before income tax | ($14.3m) | ($23.4m) | ($52.0m) | ($139.0m) | ($166.3m) | ($166.0m) | ($173.2m) | ($208.4m) | ($219.1m) | ($285.6m) | — | |
| Income tax benefit | $1.8m | $3.7m | $7.3m | $15.2m | $24.2m | $23.9m | $24.4m | $20k | $1.5m | $2.0m | — | |
| Current Income Tax Expense (Benefit) | — | — | — | ($14.7m) | ($22.8m) | ($23.8m) | ($24.2m) | $968k | $1.7m | $2.6m | $610k | |
| Net Income From Continuing And Discontinued Operation | ($12.6m) | ($19.7m) | ($44.8m) | ($123.8m) | ($142.1m) | ($142.1m) | ($148.8m) | ($208.4m) | ($220.7m) | ($287.5m) | ($289.0m) | |
| Net loss attributable to ordinary shareholders | ($12.6m) | ($19.7m) | ($44.8m) | ($123.8m) | ($142.1m) | ($142.1m) | ($148.8m) | ($208.4m) | ($220.7m) | ($287.5m) | — | |
| Earnings Per Share, Basic | ($1.26) | ($1.43) | ($1.42) | ($2.88) | ($2.76) | ($1.97) | ($1.57) | ($1.20) | ($0.86) | ($1.08) | ($1.09) | |
| Earnings Per Share, Diluted | ($1.26) | ($1.43) | ($1.42) | ($2.88) | ($2.76) | ($1.97) | ($1.57) | ($1.20) | ($0.86) | ($1.08) | ($1.09) | |
| Weighted-average basic ordinary shares (in shares) | — | — | — | $43.1m | $51.6m | $72.1m | $95.0m | $173.9m | $255.2m | $266.1m | — | |
| Weighted-average diluted ordinary shares (in shares) | — | — | — | $43.1m | $51.6m | $72.1m | $95.0m | $173.9m | $255.2m | $266.1m | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 43.1m | 51.6m | 72.1m | 95.0m | 173.9m | 255.2m | 266.1m | 266.1m | |
| Basic Average Shares | — | — | — | $43.1m | $51.6m | $72.1m | $95.0m | $173.9m | $255.2m | $266.1m | $266.1m | |
| Diluted Average Shares | — | — | — | $43.1m | $51.6m | $72.1m | $95.0m | $173.9m | $255.2m | $266.1m | $266.1m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 43.1m | 51.6m | 72.1m | 95.0m | 173.9m | 255.2m | 266.1m | 266.1m | |
| Additional Financial Items | ||||||||||||
| Loss on disposal of leasehold improvements | — | — | — | $0 | $0 | ($676k) | ($515k) | ($3.8m) | ($223k) | — | — | |
| Foreign currency exchange translation adjustment | ($2.9m) | $802k | ($6.1m) | $6.8m | $2.8m | ($2.7m) | ($30.3m) | — | — | — | — | |
| Diluted EPS | ($1.26) | ($1.43) | ($1.42) | ($2.88) | ($2.76) | ($1.97) | ($1.57) | ($1.20) | ($0.86) | ($1.08) | ($1.09) | |
| Diluted NI Availto Com Stockholders | ($12.6m) | ($19.7m) | ($44.8m) | ($123.8m) | ($142.1m) | ($142.1m) | ($148.8m) | ($208.4m) | ($220.7m) | ($287.5m) | ($289.0m) | |
| Impairment Of Capital Assets | — | — | — | — | — | $0 | $0 | $382k | $414k | — | $0 | |
| Normalized EBITDA | — | — | — | — | — | — | ($131.7m) | ($155.2m) | ($201.1m) | ($241.2m) | ($240.5m) | |
| Normalized Income | — | — | — | — | — | — | ($148.4m) | ($206.8m) | ($219.9m) | ($289.2m) | ($288.0m) | |
| Other Gand A | — | — | — | — | — | $31.9m | $31.9m | $46.7m | — | — | — | |
| Reconciled Depreciation | — | — | — | — | — | — | $7.4m | $6.6m | $7.7m | $9.8m | $10.2m | |
| Selling General And Administration | — | — | — | — | — | — | $31.9m | $46.7m | $101.7m | $131.9m | — | |
| Special Income Charges | — | — | — | — | — | ($676k) | ($515k) | ($4.2m) | ($637k) | — | ($3k) | |
| Tax Effect Of Unusual Items | — | — | — | — | — | — | ($108k) | ($140) | ($208k) | $454k | ($674k) | |
| Tax Provision | — | — | — | — | — | — | $272k | ($19k) | $1.5m | $2.0m | $610k | |
| Tax Rate For Calcs | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Operating Expense | — | — | — | — | — | — | $149.1m | $177.2m | $240.2m | $249.6m | $254.5m | |
| Total comprehensive loss | ($15.5m) | ($18.9m) | ($50.8m) | ($117.1m) | ($139.3m) | ($144.8m) | ($179.2m) | — | — | — | — | |
| Total Unusual Items | — | — | — | — | — | — | ($515k) | ($1.5m) | ($989k) | $2.2m | ($1.7m) | |
| Total other (expense) income, net | $49k | $38k | $5.5m | $7.1m | $1.9m | ($988k) | ($5.2m) | — | — | — | — | |
| Total Expenses | — | — | — | — | — | — | $149.1m | $177.2m | $251.5m | $345.9m | $357.4m |